Literature DB >> 9746121

Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension.

P Verdecchia1, G Schillaci, C Borgioni, A Ciucci, M P Telera, S Pede, R Gattobigio, C Porcellati.   

Abstract

BACKGROUND: Previous studies revealed a direct association between resting heart rate and risk of mortality in essential hypertension. However, resting heart rate is a highly variable measure since it is affected by the alerting reaction to the visit.
OBJECTIVE: To investigate whether the heart rate values recorded during the 24 h of ambulatory blood pressure monitoring are independent predictors of survival of uncomplicated subjects with essential hypertension.
METHODS: We followed up 1942 initially untreated and uncomplicated subjects with essential hypertension (mean age 51.7 years, 52% men) for an average of 3.6 years (range 0-10 years). All subjects underwent baseline procedures including 24 h non-invasive blood pressure monitoring with simultaneous assessment of heart rate, one reading every 15 min for 24 h. MAIN OUTCOME MEASURES: All-cause mortality and cardiovascular morbidity.
RESULTS: During follow-up there were 74 deaths from all causes (1.06 per 100 person-years) and 182 total (fatal plus non-fatal) cardiovascular morbid events (2.66 per 100 person-years). Clinic, average 24 h, daytime and night-time heart rates exhibited no association with total mortality. However, the subjects who subsequently died had had a blunted reduction of heart rate on going from day to night during the baseline examination. After adjustment for age (P < 0.001), diabetes (P < 0.001) and average 24 h systolic blood pressure (SBP, P= 0.002) in a Cox model, for each 10% less reduction in the heart rate from day to night the relative risk of mortality was 1.30 (95% confidence interval 1.02-1.65, P = 0.04). Rates of death were 0.38, 0.71, 0.94 and 2.0 per 100 person-years among subjects in the four quartiles of the distribution of the percentage reduction in heart rate from day to night The baseline day-night changes in the heart rate exhibited an inverse correlation to age and to clinic and ambulatory SBP and a direct association with the day-night changes in blood pressure. The degree of reduction of heart rate from day to night also had an independent inverse association with total cardiovascular morbidity after adjustment for age, diabetes and left ventricular hypertrophy, but this association did not remain significant when average 24 h SBP and the degree of day-night reduction in SBP were entered into the equation.
CONCLUSIONS: A flattened diurnal rhythm of heart rate in uncomplicated subjects with essential hypertension is a marker of risk for subsequent all-cause mortality and this association persists after adjustment for several risk factors. For assessing these subjects, a limited and uniformly distributed period of ambulatory heart rate recording during the 24 h is clinically valuable.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746121     DOI: 10.1097/00004872-199816090-00015

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

Review 1.  Ambulatory blood pressure improves prediction of cardiovascular risk: implications for better antihypertensive management.

Authors:  Lawrence R Krakoff
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

2.  Nondipping heart rate and associated factors in patients with chronic kidney disease.

Authors:  Zeynep Biyik; Yasemin Coskun Yavuz; Lütfullah Altintepe; Gulperi Celik; Ibrahim Guney; Sevıl Fısekcı Oktar
Journal:  Clin Exp Nephrol       Date:  2019-09-03       Impact factor: 2.801

3.  Nocturnal nondipping of heart rate predicts cardiovascular events in hypertensive patients.

Authors:  Kazuo Eguchi; Satoshi Hoshide; Joji Ishikawa; Thomas G Pickering; Joseph E Schwartz; Kazuyuki Shimada; Kazuomi Kario
Journal:  J Hypertens       Date:  2009-11       Impact factor: 4.844

4.  Chronic aerobic exercise improves blood pressure dipping status in African American nondippers.

Authors:  Chenyi Ling; Keith M Diaz; Jan Kretzschmar; Deborah L Feairheller; Kathleen M Sturgeon; Amanda Perkins; Praveen Veerabhadrappa; Sheara T Williamson; Hojun Lee; Heather Grimm; Dianne M Babbitt; Michael D Brown
Journal:  Blood Press Monit       Date:  2014-12       Impact factor: 1.444

5.  Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study.

Authors:  Paolo Palatini; Gianpaolo Reboldi; Lawrence J Beilin; Kazuo Eguchi; Yutaka Imai; Kazuomi Kario; Takayoshi Ohkubo; Sante D Pierdomenico; Francesca Saladini; Joseph E Schwartz; Lindon Wing; Paolo Verdecchia
Journal:  Int J Cardiol       Date:  2013-02-08       Impact factor: 4.164

6.  Ambulatory blood pressure monitoring and all-cause mortality in elderly people with diabetes mellitus.

Authors:  Walter Palmas; Thomas G Pickering; Jeanne Teresi; Joseph E Schwartz; Andrew Moran; Ruth S Weinstock; Steven Shea
Journal:  Hypertension       Date:  2009-01-05       Impact factor: 10.190

7.  Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates Angiotensin-induced hypertension.

Authors:  Rasna Sabharwal; Zhongming Zhang; Yongjun Lu; Francois M Abboud; Andrew F Russo; Mark W Chapleau
Journal:  Hypertension       Date:  2010-01-25       Impact factor: 10.190

Review 8.  Should the heart rate of hypertensive patients influence clinical decisions?

Authors:  Thomas G Pickering
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-12       Impact factor: 3.738

9.  Is the blunted fall in nighttime heart rate a marker of subclinical cardiac damage?

Authors:  Cesare Cuspidi; Marijana Tadic; Carla Sala
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-07       Impact factor: 3.738

10.  Association between nondipper pulse rate and measures of cardiac overload: The J-HOP Study.

Authors:  Yusuke Oba; Tomoyuki Kabutoya; Satoshi Hoshide; Kazuo Eguchi; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-02-03       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.